An interventional study of Nasal high-flow in Pulmonary Hypertension, sponsored by ADIR Association. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-19.
Sponsored by ADIR Association · Not applicable, Interventional, and Treatment
In this study, the investigators aim to describe the hemodynamic consequences of nasal high-flow measured during right heart catheterization and echocardiography. The research hypothesis is that nasal high-flow would increase cardiac output in patients with pulmonary hypertension. The concomitant echocardiography will allow to describe its sensibility to detect cardiovascular consequences of nasal high-flow.
1,119 studies on the registry are indexed under Hypertension, Pulmonary; 236 are open to participants now.
This study's planned enrollment of 20 is below the median of 35 across 659 interventional studies indexed under Hypertension, Pulmonary.
Browse Hypertension, Pulmonary studies →ADIR Association is the lead sponsor of 27 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- patient addressed for right heart catheterization for pulmonary hypertension suspicion or follow-up.
Exclusion Criteria:
The patient will be placed successively under nasal high-flow 30 L/min during 20 min and then 50 L/min during 20 min.
Device: Nasal high-flow
The patient will be placed successively under nasal high-flow 50 L/min during 20 min and then 30 L/min during 20 min.
Device: Nasal high-flow
Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen if necessary
Cardiac output
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
cardiac output
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
cardiac output
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
Right atrial pressure
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
Right atrial pressure
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
Right atrial pressure
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
systolic pulmonary arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
systolic pulmonary arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
systolic pulmonary arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
diastolic pulmonary arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
diastolic pulmonary arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
diastolic pulmonary arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
mean pulmonary arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
mean pulmonary arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
mean pulmonary arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
capillary wedge pressure
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
capillary wedge pressure
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
capillary wedge pressure
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
pulmonary vascular resistance
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
pulmonary vascular resistance
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
pulmonary vascular resistance
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
central venous oxygen saturation
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
central venous oxygen saturation
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
central venous oxygen saturation
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
heart rate
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
heart rate
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
heart rate
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
systolic arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
systolic arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
systolic arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
diastolic arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
diastolic arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
diastolic arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
mean arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
mean arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
mean arterial pressure
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
systolic ejection volume
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
systolic ejection volume
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
systolic ejection volume
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
respiratory rate
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
respiratory rate
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
respiratory rate
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
pulse oxygen saturation
Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
pulse oxygen saturation
Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air
Time frame: During the intervention, at isotime
pulse oxygen saturation
Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min
Time frame: During the intervention, at isotime
Consequences of nasal high-flow 50 and 30 L/min FiO2 21% on echocardiographic parameters.
Cardiac output, inferior vena cava diameter and collapsibiliy, systolic pulmoanry arterial pressure, tricuspid regurgitation velocity,tricuspid annular plane systolic excursion, right ventricule strain, tricuspid S wave, right on left ventricular telediastolic surface ratio, left ventricular ejection fraction, mitral doppler, mitral S wave, respiratory variability of E mitral wave
Time frame: During the intervention, at isotime
systolic pulmonary arterial pressure measured by catheterization and echocardiography.
Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography.
Time frame: During the intervention, at isotime
capillary wedge pressure measured by catheterization and echocardiography.
Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography.
Time frame: During the intervention, at isotime
right atrial pressure measured by catheterization and echocardiography.
Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography.
Time frame: During the intervention, at isotime
cardiac output measured by catheterization and echocardiography.
Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography.
Time frame: During the intervention, at isotime
This study is status unknown, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ADIR Association